Profile data is unavailable for this security.
About the company
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
- Revenue in SEK (TTM)3.44bn
- Net income in SEK-5.01bn
- Incorporated1989
- Employees1.15k
- LocationVitrolife ABGustaf Werners gata 2, Vastra FrolundaGOETEBORG 421 32SwedenSWE
- Phone+46 317218000
- Fax+46 317218099
- Websitehttps://www.vitrolife.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CellaVision AB | 758.97m | 153.08m | 3.62bn | 236.00 | 23.65 | 4.08 | 18.82 | 4.77 | 6.42 | 6.42 | 31.82 | 37.21 | 0.7201 | 2.02 | 6.80 | -- | 14.52 | 14.71 | 16.22 | 16.96 | 68.50 | 68.38 | 20.17 | 19.85 | 2.97 | 25.88 | 0.0281 | 41.97 | 4.94 | 9.99 | 8.78 | 11.34 | 20.76 | 29.67 |
| Medistim ASA | 634.70m | 135.20m | 3.97bn | 154.00 | 29.27 | 9.95 | 24.74 | 6.25 | 7.79 | 7.79 | 36.56 | 22.91 | 1.25 | 0.7679 | 9.67 | 4,341,637.00 | 26.72 | 21.98 | 33.09 | 27.19 | 81.21 | 78.66 | 21.30 | 20.32 | 2.03 | -- | 0.0484 | 85.04 | 6.88 | 9.12 | 0.0087 | 8.11 | 12.53 | 16.89 |
| Revenio Group Oyj | 1.17bn | 185.61m | 5.29bn | 247.00 | 28.44 | 4.31 | 22.76 | 4.52 | 0.654 | 0.654 | 4.12 | 4.31 | 0.7515 | 3.05 | 7.26 | 444,129.60 | 11.92 | 14.00 | 14.23 | 17.40 | 70.92 | 70.95 | 15.86 | 19.38 | 1.63 | 9.66 | 0.0969 | -- | 5.97 | 12.43 | -5.93 | 5.42 | 22.19 | -- |
| RaySearch Laboratories AB (publ) | 1.34bn | 227.77m | 5.90bn | 458.00 | 28.82 | 6.67 | 11.38 | 4.39 | 6.65 | 6.65 | 39.25 | 28.74 | 0.6584 | 6.25 | 2.93 | 2,935,074.00 | 11.16 | 5.26 | 16.21 | 7.77 | 92.42 | 91.01 | 16.94 | 9.70 | 1.66 | 64.92 | 0.2861 | 52.38 | 12.77 | 15.58 | 11.93 | -- | 0.2213 | -- |
| Xvivo Perfusion AB | 812.17m | 25.16m | 5.91bn | 198.00 | 235.33 | 2.79 | 61.93 | 7.27 | 0.7968 | 0.7968 | 25.76 | 67.10 | 0.34 | 0.8939 | 6.13 | 4,101,844.00 | 1.05 | 3.28 | 1.12 | 3.52 | 73.81 | 73.86 | 3.10 | 10.87 | 3.68 | 1.83 | 0.0557 | 0.00 | -1.25 | 35.19 | -85.39 | -- | -- | -- |
| Arjo AB (publ) | 11.00bn | 334.00m | 6.88bn | 6.94k | 22.07 | 0.9884 | 4.82 | 0.6252 | 1.23 | 1.23 | 40.39 | 27.38 | 0.704 | 4.92 | 6.22 | 1,584,702.00 | 2.14 | 3.26 | 2.91 | 4.80 | 42.59 | 43.42 | 3.04 | 4.78 | 0.8494 | 3.99 | 0.4179 | 48.74 | -2.59 | 3.92 | -32.93 | -8.68 | -- | 2.25 |
| ChemoMetec A/S | 703.99m | 252.73m | 10.44bn | 172.00 | 41.33 | 11.21 | 35.80 | 14.84 | 10.17 | 10.17 | 28.33 | 37.50 | 0.6516 | 0.6662 | 5.54 | 2,679,973.00 | 23.39 | 27.48 | 27.93 | 34.02 | 83.83 | 80.53 | 35.90 | 36.41 | 3.06 | 95.21 | 0.0079 | 48.77 | 21.50 | 18.28 | 36.78 | 25.80 | 19.35 | 36.08 |
| Vitrolife AB | 3.44bn | -5.01bn | 12.92bn | 1.15k | -- | 1.64 | -- | 3.76 | -37.01 | -37.01 | 25.39 | 58.29 | 0.2407 | 3.44 | 5.24 | 2,987,837.00 | -35.09 | -9.46 | -36.79 | -9.86 | 58.24 | 57.81 | -145.74 | -49.19 | 2.73 | 11.33 | 0.169 | -- | -4.68 | 22.53 | -1,077.00 | -- | 68.15 | 6.58 |
| AddLife AB | 10.44bn | 560.00m | 18.18bn | 2.30k | 33.56 | 3.45 | 13.26 | 1.74 | 4.60 | 4.60 | 85.69 | 44.66 | 0.8105 | 3.83 | 5.87 | 4,549,891.00 | 4.36 | 3.82 | 6.05 | 5.80 | 38.09 | 37.80 | 5.38 | 4.66 | 0.6257 | 3.68 | 0.4671 | 31.71 | 1.52 | 14.64 | 122.22 | 1.58 | 22.47 | 0.00 |
| Embla Medical hf | 8.38bn | 752.43m | 18.23bn | 4.19k | 24.03 | 2.25 | 13.99 | 2.17 | 1.23 | 1.23 | 13.73 | 13.17 | 0.5681 | 2.27 | 6.96 | 1,401,077.00 | 5.12 | 4.60 | 6.10 | 5.43 | 62.30 | 62.25 | 9.01 | 7.99 | 0.9445 | 7.22 | 0.3768 | 0.00 | 8.63 | 8.09 | 22.05 | 68.07 | 6.12 | -- |
| Elekta AB (publ) | 17.57bn | 292.00m | 21.40bn | 4.48k | 75.92 | 2.63 | 13.56 | 1.22 | 0.7646 | 0.7646 | 45.97 | 22.11 | 0.5781 | 3.35 | 3.09 | 3,872,796.00 | 0.9511 | 3.48 | 1.70 | 6.21 | 38.17 | 38.22 | 1.65 | 6.02 | 0.7918 | 7.51 | 0.4724 | 92.20 | -0.5685 | 4.29 | -81.80 | -26.22 | 15.56 | 5.92 |
| Asker Healthcare Group AB | 16.79bn | 492.00m | 24.65bn | 4.58k | 48.47 | -- | 18.56 | 1.47 | 1.33 | 1.33 | 45.59 | -- | 1.12 | 5.14 | 8.48 | 3,665,284.00 | 3.41 | -- | 4.52 | -- | 40.92 | -- | 3.04 | -- | 0.8497 | 3.20 | 0.4688 | -- | 11.73 | -- | 36.67 | -- | -- | -- |
Data as of Feb 27 2026. Currency figures normalised to Vitrolife AB's reporting currency: Swedish Krona SEK
22.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AMF Fonder ABas of 03 Feb 2026 | 6.34m | 4.68% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 5.41m | 3.99% |
| Fj�rde AP-fondenas of 28 Feb 2025 | 4.66m | 3.44% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.89m | 2.14% |
| Cliens Kapitalf�rvaltning ABas of 28 Feb 2025 | 2.77m | 2.05% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 2.17m | 1.60% |
| F�rsta AP-fondenas of 28 Feb 2025 | 1.83m | 1.35% |
| Premier Fund Managers Ltd.as of 31 Oct 2025 | 1.73m | 1.28% |
| SEB Funds ABas of 30 Jan 2026 | 1.41m | 1.04% |
| Andra AP-fondenas of 28 Feb 2025 | 1.37m | 1.01% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
